Our Techonology
Isla Technologies’ mission is to develop a minimally invasive cell implant to treat poorly controlled type 1 diabetes. Cells are enclosed in the proprietary bioartificial pancreas device and implanted into a recipient. After implantation, the cells within the device sense changes in glucose and secrete insulin in response. The device is meant to function for years improving patient’s glycemic control and quality of life.
Isla Technologies’ bioartificial pancreas device was conceived by Dr. Sara Photiadis during her medical education at the University of Virginia. The device is designed to improve oxygenation to the cells within the device by deploying it using minimally invasive techniques near the cardiovascular system. To achieve optimal nutrient exchange between the device and the body tissue Isla will access the flowing environment within the bloodstream, allowing for expedient diffusion of therapeutics into the blood. Isla’s technology aims to provide precise blood glucose control for years, eliminating patient’s needs for exogenous insulin therapy.
Isla Technologies’ bioartificial pancreas device was conceived by Dr. Sara Photiadis during her medical education at the University of Virginia. The device is designed to improve oxygenation to the cells within the device by deploying it using minimally invasive techniques near the cardiovascular system. To achieve optimal nutrient exchange between the device and the body tissue Isla will access the flowing environment within the bloodstream, allowing for expedient diffusion of therapeutics into the blood. Isla’s technology aims to provide precise blood glucose control for years, eliminating patient’s needs for exogenous insulin therapy.
Isla Technologies’ device uses well known biocompatible materials to support islet function and viability. While Isla Technologies’ current focus is a cell therapy for type 1 diabetes, the encapsulating technology can support multiple cell types and drug therapeutics. After validation of the proprietary bioartificial pancreas device in humans, Isla Technologies will expand use with other clinical indications.
